MetaVia (NASDAQ:MTVA) Issues Quarterly Earnings Results, Beats Estimates By $0.25 EPS

MetaVia (NASDAQ:MTVA) announced its earnings results on Friday. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.25, FiscalAI reports.

MetaVia Trading Up 4.9%

Shares of MTVA traded up $0.06 during mid-day trading on Friday, reaching $1.36. The company’s stock had a trading volume of 36,409 shares, compared to its average volume of 1,228,414. The stock has a market cap of $7.04 million, a PE ratio of -0.42 and a beta of 1.24. MetaVia has a 52 week low of $0.97 and a 52 week high of $13.42. The company’s fifty day moving average price is $1.47 and its two-hundred day moving average price is $1.62.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MetaVia in a research note on Monday, October 19th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $20.00.

MetaVia Company Profile

MetaVia, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases. Its work is centered on conditions such as obesity, diabetes and other disorders associated with metabolic dysfunction. The company’s activities primarily involve the discovery, development and clinical evaluation of potential drug candidates intended to address significant unmet medical needs in metabolic health. As a development-stage biotechnology company, MetaVia’s operations are focused on research programs and advancing therapies through clinical testing rather than on commercialized products.